Weinstein Kaplan, Bette
January 2013
Oncology Nurse Advisor;January/February 2013, Vol. 4 Issue 1, p38
The article offers information on Perjeta or pertuzumab, a Human Epidermal Growth Factor Receptor 2 (HER2) antagonist indicated for the treatment of HER2-positive metastatic breast cancer. It explains the drug's mechanism of action and the recommended dosage and administration. It also discusses some of its side effects which include fetal toxicity, hypersensitivity reactions and decreased left ventricular ejection fraction (LVEF).


Related Articles

  • Immunogenicity of Biotherapeutics: A Need for Consensus on Flexibility of Approach. Barker, Stewart // Current Drug Safety;Oct2010, Vol. 5 Issue 4, p272 

    An introduction is presented in which the editor discusses various reports within the issue on topics including monoclonal antibodies, immunogenicity of drugs in development, and the basis of the immune system that determines the immunogenicity of foreign proteins in humans.

  • STAT CONSULT. Weinstein Kaplan, Bette; Pereiras, Maribel // Oncology Nurse Advisor;Nov/Dec2011, Vol. 2 Issue 6, p31 

    No abstract available.

  • Brentuximab vedotin: An anti-CD30 antibody--drug conjugate. Bradley, Amber M.; Devine, Meghan; Deremer, David // American Journal of Health-System Pharmacy;4/1/2013, Vol. 70 Issue 7, p589 

    Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety and tolerability of brentuximab vedotin are reviewed. Summary. Brentuximab vedotin is a potent antibody-drug conjugate composed of the monoclonal antibody cAC10, which targets the CD30 antigen on Hodgkin lymphoma and...

  • Ustekinumab: a guide to its use in plaque psoriasis. Keating, Gillian M.; Croxtall, Jamie D. // Drugs & Therapy Perspectives;Aug2012, Vol. 28 Issue 8, p6 

    Subcutaneous ustekinumab (Stelara®) improves symptoms in patients with moderate to severe plaque psoriasis and is more effective than etanercept. Subcutaneous ustekinumab is generally well tolerated, with infections being the most commonly reported adverse event.

  • Obinutuzumab (Gazyva).  // Oncology Nurse Advisor;May/Jun2014, Vol. 5 Issue 3, p30 

    No abstract available.

  • Ramucirumab (Cyramza).  // Oncology Nurse Advisor;Nov/Dec2014, Vol. 5 Issue 6, p41 

    No abstract available.

  • Intravenous lupus treatment approved.  // Clinical Advisor;May2011, Vol. 14 Issue 5, p31 

    The article focuses on Benlysta, a new drug approved for intravenous lupus treatment. It mentions that the drug is a human immunoglobulin (Ig) G1gamma monoclonal antibody for human B lymphocyte stimulator protein (BLyS). It also provides information on the three randomized, placebo-controlled...

  • Safety of Therapeutic Monoclonal Antibodies. Niebecker, Ronald; Kloft, Charlotte // Current Drug Safety;Oct2010, Vol. 5 Issue 4, p276 

    Therapeutic monoclonal antibodies (mAbs) including antibody fusion proteins and antibody conjugates present an innovative class of (bio-)pharmaceuticals with increasing clinical importance. MAbs were initially perceived as comparatively safe drugs. As more mAbs appear on the market,...

  • Novel Therapies for Asthma - Advances and Problems. Walsh, Garry M. // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 23, p3027 

    It is now widely accepted that airway inflammation is the key factor underlying the pathogenesis of asthma. While corticosteroids remain the most important anti-inflammatory treatment for asthma they are rather non-specific in their actions. Their use also raises concerns over side effects and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics